A Chimeric Japanese Encephalitis Vaccine Protects against Lethal Yellow Fever Virus Infection without Inducing Neutralizing Antibodies.
Animals
Antibodies, Neutralizing
Antibodies, Viral
/ blood
Cross Protection
HEK293 Cells
Humans
Japanese Encephalitis Vaccines
/ genetics
Male
Mice
T-Lymphocytes
/ immunology
Vaccines, Synthetic
/ administration & dosage
Viral Nonstructural Proteins
/ immunology
Yellow Fever
/ immunology
Yellow fever virus
antibody-dependent cellular cytotoxicity (ADCC)
antibody-dependent enhancement
chimeric YFV-17D vaccine
chimeric flavivirus vaccine
cross-protection
dual protection
flavivirus
nonneutralizing antibodies
off-label use of vaccine
protective T cell responses
Journal
mBio
ISSN: 2150-7511
Titre abrégé: mBio
Pays: United States
ID NLM: 101519231
Informations de publication
Date de publication:
07 04 2020
07 04 2020
Historique:
entrez:
9
4
2020
pubmed:
9
4
2020
medline:
18
2
2021
Statut:
epublish
Résumé
Recent outbreaks of yellow fever virus (YFV) in West Africa and Brazil resulted in rapid depletion of global vaccine emergency stockpiles and raised concerns about being unprepared against future YFV epidemics. Here we report that a live attenuated virus similar to the Japanese encephalitis virus (JEV) vaccine JE-CVax/Imojev that consists of YFV-17D vaccine from which the structural (prM/E) genes have been replaced with those of the JEV SA14-14-2 vaccine strain confers full protection in mice against lethal YFV challenge. In contrast to the YFV-17D-mediated protection against YFV, this protection is not mediated by neutralizing antibodies but correlates with YFV-specific nonneutralizing antibodies and T cell responses against cell-associated YFV NS1 and other YFV nonstructural (NS) proteins. Our findings reveal the potential of YFV NS proteins to mediate protection and demonstrate that chimeric flavivirus vaccines, such as Imojev, could confer protection against two flaviviruses. This dual protection may have implications for the possible off-label use of JE-CVax in case of emergency and vaccine shortage during YFV outbreaks. In addition, populations in Asia that have been vaccinated with Imojev may already be protected against YFV should outbreaks ever occur on that continent, as several countries/regions in the Asia-Pacific are vulnerable to international spread of the YFV.
Identifiants
pubmed: 32265332
pii: mBio.02494-19
doi: 10.1128/mBio.02494-19
pmc: PMC7157777
pii:
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Japanese Encephalitis Vaccines
0
NS1 protein, Flavivirus
0
Vaccines, Synthetic
0
Viral Nonstructural Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2020 Mishra et al.
Références
Hum Vaccin. 2006 Mar-Apr;2(2):60-7
pubmed: 17012873
NPJ Vaccines. 2018 Dec 13;3:56
pubmed: 30564463
Sci Rep. 2017 Apr 6;7(1):662
pubmed: 28386132
Cell Host Microbe. 2010 Nov 18;8(5):410-21
pubmed: 21075352
Clin Microbiol Infect. 2018 Jul;24(7):680-681
pubmed: 29581052
Vaccine. 2012 May 2;30(21):3180-7
pubmed: 22425792
mBio. 2017 Feb 7;8(1):
pubmed: 28174309
J Gen Virol. 1991 Nov;72 ( Pt 11):2811-6
pubmed: 1834798
J Gen Virol. 1990 Aug;71 ( Pt 8):1697-702
pubmed: 2144016
J Clin Epidemiol. 2018 Mar;95:137-139
pubmed: 29180056
PLoS Pathog. 2009 Oct;5(10):e1000614
pubmed: 19816561
Cell Host Microbe. 2016 Jun 8;19(6):882-90
pubmed: 27212660
PLoS One. 2011;6(10):e26494
pubmed: 22039500
Vaccine. 2015 Jan 1;33(1):76-7
pubmed: 24852721
J Virol. 1990 Sep;64(9):4356-63
pubmed: 2143542
Proc Natl Acad Sci U S A. 2002 Jul 9;99(14):9322-7
pubmed: 12080145
J Exp Med. 2010 Apr 12;207(4):793-806
pubmed: 20308361
J Virol. 2013 Dec;87(24):13694-705
pubmed: 24109223
J Exp Med. 1937 May 31;65(6):787-800
pubmed: 19870634
Pediatr Infect Dis J. 2010 Dec;29(12):1111-7
pubmed: 20856164
J Virol. 2015 Jun;89(12):6494-505
pubmed: 25855749
Hum Vaccin. 2010 Nov;6(11):906-14
pubmed: 20864814
Protein Cell. 2017 Mar;8(3):225-229
pubmed: 28124229
mBio. 2019 Apr 2;10(2):
pubmed: 30940710
J Virol. 2001 Jan;75(2):934-42
pubmed: 11134306
PLoS Pathog. 2012;8(10):e1002934
pubmed: 23055924
Nat Microbiol. 2016 Sep 19;1:16164
pubmed: 27642668
Proc Natl Acad Sci U S A. 2013 May 14;110(20):E1867-76
pubmed: 23630248
N Engl J Med. 2016 Apr 21;374(16):1552-63
pubmed: 27028561
Rev Bras Hematol Hemoter. 2012;34(1):25-30
pubmed: 23049380
Theranostics. 2017 Feb 12;7(4):912-925
pubmed: 28382163
PLoS Negl Trop Dis. 2016 May 10;10(5):e0004695
pubmed: 27163257
Hum Vaccin Immunother. 2013 Nov;9(11):2317-25
pubmed: 23839107
Int J Infect Dis. 2016 Jul;48:98-103
pubmed: 27156836
Emerg Microbes Infect. 2016 Jul 13;5(7):e69
pubmed: 27406389
Vaccine. 2008 Oct 23;26(45):5712-21
pubmed: 18762226
PLoS Negl Trop Dis. 2013;7(1):e1938
pubmed: 23383350
J Virol. 1999 Apr;73(4):3095-101
pubmed: 10074160
Vaccine. 2014 Jan 3;32(2):258-64
pubmed: 24252694
Clin Vaccine Immunol. 2009 Jul;16(7):1052-9
pubmed: 19458204
J Immunol. 2009 Dec 15;183(12):7919-30
pubmed: 19933869
J Immunol Methods. 2014 Dec 1;414:69-81
pubmed: 25086226
Vaccine. 2014 Mar 10;32(12):1326-37
pubmed: 24486372
Vaccine. 2015 Jan 1;33(1):62-72
pubmed: 25446819
MMWR Morb Mortal Wkly Rep. 2017 May 05;66(17):457-459
pubmed: 28472025
J Gen Virol. 1986 Apr;67 ( Pt 4):631-7
pubmed: 3958694
PLoS Curr. 2016 Nov 15;8:
pubmed: 28018746
Cell Host Microbe. 2008 Sep 11;4(3):229-38
pubmed: 18779049
J Virol. 2013 Dec;87(23):12794-804
pubmed: 24049183
J Exp Med. 2005 Nov 7;202(9):1179-84
pubmed: 16260489
PLoS Pathog. 2016 Jul 27;12(7):e1005786
pubmed: 27463517
J Virol. 2005 Jul;79(13):8004-13
pubmed: 15956546
J Immunol. 2015 Feb 1;194(3):1141-53
pubmed: 25539816
J Virol Methods. 2012 Aug;183(2):176-9
pubmed: 22575574
N Engl J Med. 2017 Apr 13;376(15):1483-1485
pubmed: 28402771
J Virol. 2006 Oct;80(19):9557-68
pubmed: 16973559
Curr Opin Virol. 2016 Jun;18:64-9
pubmed: 27093699
Hum Vaccin Immunother. 2014;10(12):3579-93
pubmed: 25668666
NPJ Vaccines. 2018 Jan 23;3:5
pubmed: 29387474
PLoS Negl Trop Dis. 2016 Feb 17;10(2):e0004464
pubmed: 26886513
J Gen Virol. 2003 May;84(Pt 5):1261-1268
pubmed: 12692292
J Infect Dis. 2003 Oct 15;188(8):1213-30
pubmed: 14551893
Curr Protoc Immunol. 2001 May;Chapter 4:Unit 4.1
pubmed: 18432792
J Virol. 1986 Dec;60(3):1153-5
pubmed: 3783816
Science. 1993 Mar 19;259(5102):1742-5
pubmed: 8456301
J Gen Virol. 1990 Mar;71 ( Pt 3):593-9
pubmed: 2138210
J Clin Microbiol. 2015 Feb;53(2):557-66
pubmed: 25502522
J Gen Virol. 2015 Jun;96(Pt 6):1328-1339
pubmed: 25646269
Lancet Infect Dis. 2017 Mar;17(3):248-250
pubmed: 28017560
Vaccine. 1999 Apr 9;17(15-16):1869-82
pubmed: 10217584
Sci Rep. 2016 Jan 28;6:19953
pubmed: 26818736
Virology. 1983 Feb;125(1):8-17
pubmed: 6187129
Virology. 1993 Jan;192(1):132-41
pubmed: 8517015
Virol J. 2016 Jul 29;13:131
pubmed: 27473856
J Gen Virol. 1986 Mar;67 ( Pt 3):591-5
pubmed: 3950582
Clin Infect Dis. 2018 Feb 1;66(4):641-642
pubmed: 29088406
J Virol. 2007 Sep;81(17):9551-5
pubmed: 17582005
N Engl J Med. 2016 Jul 28;375(4):301-3
pubmed: 27276108
J Virol. 2010 Apr;84(7):3503-15
pubmed: 20106931
J Immunol. 2013 Mar 1;190(5):2150-8
pubmed: 23338234